A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
Part of paid clinical trials in Campbell, California.
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
- Study ID
- NCT04480463
- Phase
- PHASE3
- Status
- Completed
Conditions
- Neovascular Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- SCD411 — DRUGIVT (intravitreal) injection
- Aflibercept — DRUGIVT injection
Study Details
Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal blood vessels grow under the macula at the back of the eye, and also leak blood and fluid, which damages and scars the macula, affecting vision. The current standard of care for patients with neovascular (exudative / wet) AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy, which prevents or slows down the growth of the abnormal blood vessels. SCD411 is being developed as a biosimilar to the reference product Eylea® (aflibercept), an anti-VEGF drug. The study aims to prove equivalence of SCD411 to Eylea in adults with wet AMD, and will look at safety, tolerance, effectiveness, immune response and the movement of the drug through the body.
Key Dates
- Start date
- Aug 13, 2020
- Status verified
- Oct 2023
- Primary completion
- Sep 8, 2022
- Completion
- Sep 8, 2022
Study Design
- Enrollment
- 576 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: SCD411
- Active Comparator: Aflibercept
Primary Outcome Measure
Change From Baseline in BCVA (Best Corrected Visual Acuity) [ Time Frame: Baseline to Week 8 ]
Locations (12)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| SCD Research Site | Campbell | California | 95008 | - |
| SCD Research Site | Clearwater | Florida | 33761 | - |
| SCD Research Site | Coral Springs | Florida | 33067 | - |
| SCD Research Site | Fort Myers | Florida | 33912 | - |
| SCD Research Site | Stuart | Florida | 34994 | - |
| SCD Research Site | Marietta | Georgia | 30060 | - |
| SCD Research Site | Lemont | Illinois | 60439 | - |
| SCD Research Site | Liverpool | New York | 13088 | - |
| SCD Research Site | Springfield | Oregon | 97477 | - |
| SCD Research Site | Rapid City | South Dakota | 57701 | - |
| SCD Research Site | Abilene | Texas | 79606 | - |
| SCD Research Site | Willow Park | Texas | 76087 | - |
Find similar trials in Campbell, CA
Related Studies
- Extension Study for the Port Delivery System With Ranibizumab (Portal)PHASE3 · Recruiting · Hoffmann-La Roche · Phoenix, Arizona
- Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyPHASE2 · Enrolling By Invitation · AbbVie · Phoenix, Arizona
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)PHASE4 · Recruiting · Genentech, Inc. · Mesa, Arizona
- Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDPHASE3 · Recruiting · AbbVie · Phoenix, Arizona